Key Words: sex ual side ef fects, bupropion, moclobemide, paroxetine, sertraline, venlafaxine, ma jor de pres sive dis or der, nat u ral is tic B e cause ther a peu tic ef fi cacy across an ti de pres sants (ADs) is gen er ally com pa ra ble, most cli ni cians per ceive dif ferences in the in ci dence of side ef fects to be an im por tant fac tor in their se lec tion of ADs (1). How ever, very few stud ies have di rectly com pared side ef fects across the se lec tive se ro to nin reuptake in hib i tors (SSRIs) and other novel ADs. In stead, cli - Ob jec tive: There is no com monly ac cepted stan dard for com par ing antidepressant-induced side ef fects. This study evalu ates a clinician-administered scale, the To ronto Side Ef fect Scale (TSES), in a natu ral prac tice clinic.
This in ves ti ga tion com pares the side ef fects of 5 fre quently pre scribed AD med i ca tions (venlafaxine, a se ro to nin and norepinephrine reuptake in hib i tor [SNRI] ; paroxetine and sertraline, SSRIs; moclobemide, a re vers ible in hib i tor of monoamine oxidase A [RIMA] ; and bupropion, a norepinephrine and do pa mine mod u la tor [NDM] ) in a sam ple of de pres sion pa tients who were as sessed and treated un der nat u ral prac tice con di tions in an out pa tient clinic. We proposed to dem on strate dif fer ences in class-specific prevalences of side ef fects con sis tent with those found in metaanalyses and ran dom ized con trolled tri als (RCTs). We also pro posed that in ten sity, as a prod uct of fre quency and sever ity of side ef fects, would fur ther dif fer en ti ate ADs, both across and within classes.
Method
Our sub jects were out pa tients with uni po lar, nonpsychotic ma jor de pres sive dis or der (MDD) who pro vided in formed con sent and were treated at the De pres sion Clinic, Cen tre for Ad dic tion and Men tal Health (CAMH), a ter tiary care fa cil ity af fil i ated with the Uni ver sity of To ronto. En try cri te ria were a cur rent di ag no sis of ma jor de pres sive ep i sode (MDE) ac cording to DSM-IV cri te ria, a score of 16 or greater on the 17-item Ham il ton Rat ing Scale for De pres sion (HRSD-17) (5), absence of con cur rent ac tive med i cal ill ness, ab sence of AD or other psychotropic med i ca tions for a min i mum of 2 weeks (5 weeks for fluoxetine), and ab sence of ex po sure to electroconvulsive ther apy (ECT) for at least 3 months prior to treat ment ini ti a tion. The study was ap proved by the CAMH Re search Eth ics Board.
Mea sure and De sign
The To ronto Side Ef fect Scale (TSES) is a 32-item in stru ment that uses di rect phy si cian in quiry to elicit ad verse events. Mod ified from a pre vi ous in stru ment de vel oped by Healy (6), the TSES is de signed to es tab lish in ci dence, fre quency, and se ver ity of cen tral ner vous sys tem (CNS), gas tro in tes ti nal (GI), and sex ual side ef fects (see Ap pen dix). For each side effect, fre quency and se ver ity were mea sured on a 5-point Likert scale. An "in ten sity" score was de rived by mul ti ply ing fre quency by se ver ity.
Clin i cal re search as sis tants with ex ten sive ex pe ri ence and estab lished interrater re li abil ity ad min is tered the Struc tured Clin i cal In ter view for DSM-IV Axis I Dis or ders (SCID-I) (7) and the HRSD-17 to all sub jects prior to treat ment (Time 1). The treat ing phy si cian com pleted the TSES.
ADs were se lected at the dis cre tion of the treat ing psy chi a trist from among var i ous med i ca tions used in the De pres sion Clinic; how ever, dur ing this study only 5 med i ca tions were pre scribed at a rate that pro vided suit able num bers for data anal y sis. Dur ing the study, cli ni cians pro vided stan dard clin ical man age ment ev ery 2 weeks, while re peat mea sures of HRSD-17 and TSES (com pleted by the same re search staff, who were blind to which of the 5 med i ca tions had been prescribed) were col lected af ter 8 weeks of treat ment (Time 2).
Re mis sion was de fined as a fi nal HRSD-17 score < 7 af ter 8 weeks of treat ment.
Sta tis ti cal Anal y ses
We cal cu lated mean dif fer ences for con tin u ous vari ables across AD med i ca tion groups us ing a 1-way anal y sis of variance (ANOVA). We used chi-square anal y ses to ex am ine differ ences in the in ci dence rates of side ef fects be tween pairs of AD med i ca tions (for ex am ple, venlafaxine vs moclobemide) for the non con tin u ous vari ables. We used point biserial cor rela tions to ex am ine the re la tion be tween re sponse to treat ment and side ef fects, and we used a re peated-measures ANOVA to ex am ine treat ment re sponse from Time 1 to Time 2.
Results

Sociodemographic and Clin i cal Vari ables
There were no sig nif i cant dif fer ences among AD med i ca tion con di tions with re spect to age, so cio eco nomic sta tus (8) , du ration of cur rent ep i sode, age at first on set, ed u ca tion, or baseline HRSD-17 scores. Dur ing the time in ter val for this study (from Jan u ary 1, 1995, to March 31, 2000), 217 pa tients (86 men and 131 women) com pleted base line as sess ments. The sam ple was pre dom i nantly white. Of the sam ple, 193 (73 men and 120 women) com pleted the pro to col af ter at least 8 weeks of treat ment; 24 pa tients dropped out of treat ment be fore the week 8 as sess ment. There were no sig nif i cant dif fer ences between com plet ers and noncompleters. There were no sig nif icant dif fer ences in drop out rates among the 5 AD med i ca tions (bupropion 12%, venlafaxine 13%, moclobemide 16%, paroxetine 23%, and sertraline 24%), nor were there sig nif icant dif fer ences in rates of re mis sion or in re duc tion in HRSD scores (Ta ble 1). A post hoc power anal y sis us ing a me dium ef fect size (that is, Co hen's d > 0.50 < 0.79) pro duced a power of 0.84 for the 193 pa tients who com pleted the study. Thus, it is un likely that these nonsignificant re sults were at trib ut able to in suf fi cient power.
In ten sity of Side Ef fects
When the in ten sity of po ten tial side ef fects across the AD med i ca tions was ex am ined af ter Bonferroni cor rec tion, only 1 side ef fect (de layed ejac u la tion) pro duced a sta tis ti cally signif i cant dif fer ence among drugs (F = 6.89, P < 0.001). Unplanned, post hoc test ing us ing the Scheffé test in di cated that for this side ef fect pa tients on paroxetine scored sig nif i cantly higher on the in ten sity rat ing than did pa tients on other ADs.
In ci dence Rates of Side Ef fects
We then ex am ined mean score dif fer ences for the fre quency or ab so lute in ci dence rate of side ef fects. Paired com par i sons (with Bonferroni cor rec tion) re vealed sig nif i cant dif fer ences be tween at least 1 drug pair for 16 of 32 items: 7 CNS side effects, 7 GI side ef fects, and 2 sex ual func tion ing (SF) side effects (see Ta bles 2, 3, and 4 re spec tively).
CNS Side Ef fects
No CNS side ef fects were re ported sig nif i cantly more frequently with venlafaxine or paroxetine than with any other drug pair ing. Sertraline pro duced a sig nif i cantly higher in cidence of tremor and sweat ing, com pared with moclobemide, and a greater in ci dence of tremor, com pared with paroxetine. Dif fers from re sults for bupropion, P < 0.05; mean sig nifi cantly dif fers from all oth ers: Ven la fax ine, P < 0.01; ser tra line, P < 0.001; mo clobe mide, P < 0.001; bupropion, P < 0.05 b Re mis sion was de fined as a score of 7 or less on the HRSD-17
hypotension, com pared with paroxetine. It was also as so ciated with a higher in ci dence of ner vous ness and edema, compared with paroxetine and venlafaxine.
GI Side Ef fects
Dry mouth was re ported by 35% or more pa tients across all 5 groups but was not sig nif i cantly dif fer ent across drugs. The in ci dence of nau sea was sig nif i cantly greater with venlafaxine, com pared with moclobemide and bupropion, while the in ci dence of con sti pa tion was sig nif i cantly greater with paroxetine, com pared with moclobemide. Bupropion treat ment was as so ci ated with a sig nif i cantly in creased frequency of re ported weight loss, com pared with paroxetine. No GI side ef fects were more fre quent with moclobemide.
SF Side Ef fects
De layed ejac u la tion in men was re ported sig nif i cantly more fre quently with paroxetine, com pared with bupropion or sertraline, and more fre quently with venlafaxine, com pared with sertraline. In creased li bido in both men and women was re ported sig nif i cantly more fre quently with bupropion, compared with paroxetine or sertraline. No more sex ual side effects were re ported by pa tients on moclobemide, com pared with any of the other ADs.
Discussion
Equiv a lent ef fec tive ness and re mis sion rates among an ti depres sants in a nat u ral prac tice set ting were as so ci ated with het er o ge ne ity of side ef fects across drug classes and, in the a Pre ma ture ejacu la tion, de layed ejacu la tion, and erec tile dys func tion were asked of male pa tients only and were not re ported for mo clobemide due to small sam ple size.
b Dif fers from re sults for bup ropion, P < 0.05; B Dif fers from re sults for bup ropion, P < 0.01 m Dif fers from re sults for moclobe mide, P < 0.05; M Dif fers from re sults for moclobe mide, P < 0.01 p Dif fers from re sults for par oxet ine, P < 0.05; P Dif fers from re sults for par oxet ine, P < 0.01 s Dif fers from re sults for ser tra line, P < 0 .05; S Dif fers from re sults for ser tra line, P < 0.01 v Dif fers from re sults for ven la fax ine, P < 0.05; V Dif fers from re sults for ven la fax ine, P < 0.01
case of sertraline and paroxetine, within the same class. Contrary to what was pro posed, no sin gle AD pro duced a sig nif icantly greater side-effect bur den, yet among the 32 side ef fects ex am ined, 16 showed sig nif i cant dif fer ences in in cidence across a to tal of 10 drug pair ings. This val i dates cli nician AD se lec tion based on in di vid ual tolerability, while as sum ing uni form ef fec tive ness.
These re sults are sur pris ingly con sis tent with those found in RCTs com par ing 2 or more ADs. In a metaanalysis de signed to com pare ad verse ef fects as so ci ated with SSRIs and tricyclic an ti de pres sants (TCAs), nau sea, an orexia, di ar rhea, in som nia, ner vous ness, anx i ety, and ag i ta tion oc curred signif i cantly more of ten with SSRIs, com pared with TCAs (4). How ever, these au thors did not in clude sex ual dys func tion in their anal y sis. Sev eral other in ves ti ga tions of sex ual dys function pro duced find ings sim i lar to ours. Montejo-González and oth ers re ported sig nif i cantly more anorgasmia as so ci ated with paroxetine than with sertraline (48% and 37%, re spectively), as well as a higher rate of de layed ejac u la tion (9). Modell and oth ers re ported sig nif i cantly lower rates of sex ual side ef fects with bupropion, com pared with SSRIs (10). Kennedy and oth ers re ported lower lev els of sex ual dys func tion in women dur ing treat ment with moclobemide and venlafaxine, com pared with paroxetine and sertraline (11) . Our re sults were also con sis tent with those found for ag i ta tion, nau sea, and di ar rhea in a co hort study car ried out in a pri mary care setting (12) .
Metaanalyses of PDR and CPS data were per formed re spectively by Dewan and Anand (1) and Vida and Looper (13) .
Using cat e go ries sim i lar to those in our study, Dewan and Anand (1) as signed "pen alty" scores for CNS, GI, and sex ual side ef fects across SSRIs and novel an ti de pres sants, based on cal cu lated drug pla cebo dif fer ences. Bupropion, citalopram, nefazodone, and mirtazapine re ceived the low est over all scores, while fluvoxamine, paroxetine, sertraline, venlafaxine, and fluoxetine were all ranked higher.
What this study dem on strates is an im por tant de gree of variabil ity in side-effect re port ing across stud ies and a need for clin i cal stud ies to ac count for the ef fect of past ther a peu tic inter ven tions on pa tient re sponse. Most pa tients in nat u ral is tic set tings are not phar ma co log i cally na ive and do not re main on the same an ti de pres sant dos age for the du ra tion of treat ment, which may re sult in cross-tolerance or change side-effect report ing. De spite a need for con sis tency in side-effect def i nitions, it may also be ar gued that us ing a tool such as the TSES in tro duces sug gest ibil ity and in creases side-effect re port ing. Trindade and oth ers con cluded that their re sults did not depend on the method of elic it ing ad verse ef fects (4) . A search of Medline, how ever, re vealed that most such stud ies to date do not use spe cific side-effect ques tion ing, and in ci dence rates were higher in our study than in these, de spite rel a tively low mean dos ing across ADs. In ad di tion, in clud ing a greater num ber of side ef fects de creases the like li hood that dif ferences will achieve sta tis ti cal sig nif i cance, al though be tween-drug dif fer ences may be ex tremely clin i cally sig nif icant. The ad di tional di men sion of in ten sity, cal cu lated as the prod uct of fre quency and se ver ity, did not add sen si tiv ity to our mea sures and only dis tin guished one drug from the oth ers on the ba sis of sex ual dys func tion.
In sum mary, we have de vel oped and eval u ated a clin i cal in terview side-effect ques tion naire (the TSES) that as sesses both the fre quency and the se ver ity of com mon AD side ef fects. The ab sence of a pla cebo treat ment group lim its any con clusions about the prev a lence of these ef fects, com pared with pla cebo. How ever, us ing a nat u ral prac tice pop u la tion to compare side ef fects across fre quently pre scribed ADs pro vides im por tant com ple men tary data to iniformation de rived from RCTs. Un til newer agents with sig nif i cantly su pe rior rates of re mis sion, com pared with ex ist ing agents, are avail able, selecting ADs based on side-effect pro files ap pears to be justified.
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